Craig Wheeler, Momenta CEO (Michael Fein, Bloomberg via Getty Images)

J&J inks in­dus­try's lat­est bolt-on buy­out with $6.5B deal to ac­quire Mo­men­ta, beef­ing up its au­toim­mune pipeline

J&J has struck a deal to buy out Mo­men­ta $MN­TA for $6.5 bil­lion, build­ing up the au­toim­mune sec­tion of the phar­ma gi­ant’s pipeline and adding a prime late-stage drug can­di­date to the mix.

Ear­ly Wednes­day J&J put out word that it is pay­ing $52.50 a share to bag the com­pa­ny. The deal nets out at $6.1 bil­lion once you fac­tor in cash on hand at the biotech.

The prize for J&J is nipocal­imab (M281), which the com­pa­ny de­scribes as a “clin­i­cal­ly val­i­dat­ed, po­ten­tial­ly best-in-class an­ti-FcRn an­ti­body” with po­ten­tial in a range of dis­eases like ma­ter­nal-fe­tal dis­or­ders, neu­ro-in­flam­ma­to­ry dis­or­ders, rheuma­tol­ogy, der­ma­tol­ogy and au­toim­mune hema­tol­ogy. That qual­i­fies as a pipeline in a prod­uct, a key theme these days in M&A.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.